This drug is FDA-approved for treating BRAF-mutant melanoma68 and non-small cell lung cancer69 in combination with the BRAF inhibitor encorafenib and is undergoing Phase II clinical trials for pediatric low-grade gliomas and other Ras/Raf/ERK pathway-activated tumors (NCT02285439). The gene discussed is BRAF; the disease is central nervous system cancer.